Jonathan Zalevsky Sells 180 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 180 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $73.00, for a total value of $13,140.00. Following the transaction, the insider directly owned 21,174 shares of the company’s stock, valued at $1,545,702. This represents a 0.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Jonathan Zalevsky also recently made the following trade(s):

• On Tuesday, January 20th, Jonathan Zalevsky sold 3,867 shares of Nektar Therapeutics stock. The shares were sold at an average price of $35.67, for a total transaction of $137,935.89.
• On Tuesday, November 25th, Jonathan Zalevsky sold 1,157 shares of Nektar Therapeutics stock. The shares were sold at an average price of $54.28, for a total transaction of $62,801.96.

Nektar Therapeutics Price Performance

Shares of NKTR opened at $73.73 on Friday. Nektar Therapeutics has a 12-month low of $6.45 and a 12-month high of $74.89. The stock has a market capitalization of $1.50 billion, a P/E ratio of -9.25 and a beta of 1.34. The firm’s 50 day moving average is $45.81 and its 200-day moving average is $48.54.

Key Stories Impacting Nektar Therapeutics

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: Zacks Research raised multiple multi‑quarter and full‑year EPS projections (FY2026 and FY2027 were revised to smaller losses), indicating improved analyst expectations for Nektar’s future results — a generally constructive signal for the stock. MarketBeat NKTR
• Positive Sentiment: Nektar announced research collaboration with UCSF to test a TNFR2‑agonist/antibody approach in multiple sclerosis — a meaningful pipeline development that could add long‑term value if clinical data are positive. MSNewsToday: UCSF, Nektar team BioWorld: TNFR2 agonism in MS
• Neutral Sentiment: An AAII piece compared Nektar to another biotech (Harmony Biosciences) as an investment choice — useful context for longer‑term investors but unlikely to move the stock materially on its own. AAII comparison article
• Negative Sentiment: Zacks cut near‑term quarter estimates for Q2 2026 (and separately trimmed Q2 2027), signaling some expected near‑term pressure to results that can weigh on sentiment. MarketBeat NKTR

Hedge Funds Weigh In On Nektar Therapeutics

Large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its position in shares of Nektar Therapeutics by 93.8% in the third quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 210 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in Nektar Therapeutics in the 2nd quarter valued at approximately $39,000. Headlands Technologies LLC purchased a new stake in Nektar Therapeutics in the 2nd quarter worth approximately $65,000. Integrated Wealth Concepts LLC purchased a new stake in Nektar Therapeutics in the 1st quarter worth approximately $68,000. Finally, Quarry LP acquired a new stake in shares of Nektar Therapeutics during the 4th quarter valued at $85,000. Institutional investors and hedge funds own 75.88% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on NKTR. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nektar Therapeutics in a research report on Monday, December 29th. Citigroup assumed coverage on shares of Nektar Therapeutics in a research note on Wednesday, November 26th. They set a “buy” rating and a $102.00 price objective for the company. BTIG Research lifted their target price on shares of Nektar Therapeutics from $118.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. HC Wainwright boosted their price target on shares of Nektar Therapeutics from $135.00 to $165.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Nektar Therapeutics in a research report on Wednesday, December 17th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Nektar Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $119.86.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.